|
Laboratory Staff
Curriculum Vita
|
|
|
Curriculum Vita
  Verena Göbel (Bier), MD
Assistant Professor of Pediatrics
GENERAL INFORMATION
Name: Verena Göbel (Bier)
Office Address:
Massachusetts General Hospital,
Building 114, Room 3700,
16th Street,
Charlestown, MA 02129
E-mail: gobel@helix.mgh.harvard.edu
Phone: 617-726-4171
Fax: 617-726-4172
Place of Birth: Siegen, Germany
Education:
1979 M.A. Philosophy/Literature/Art History, Freie Universität Berlin, Germany, summa cum laude
1984 M.D. Freie Universität Berlin and Heinrich-Heine Universität Düsseldorf Germany (1986 Dissertation in Medicine)
Postdoctoral Training:
1984-1990 Intern and Resident in Pediatrics, Clinical and Research Fellow in Pediatric Hematology/Oncology/Immunology (H Jürgens, W Brandeis, KM Debatin and P Krammer), Children’s Hospitals and German Cancer Research Center, Universites Düsseldorf and Heidelberg, Germany
1990-1992 Fellow in Molecular Biology , National Cancer Institute, Bethesda, MD (TA Waldmann and IR Kirsch)
1992-1993 Visiting Clinical Fellow in Pediatric Hematology-Oncology, Massachusetts General Hospital and Research Fellow in Molecular Genetics, Massachusetts General Hospital Cancer Center, Boston MA (S Friend)
Licensure and Certification:
1984 Medical Licensure Germany
1991 US Medical Examination in Basic and Clinical Sciences, Educational Commission for Foreign Medical Graduates
1992 German Board of Pediatrics
1993 US Federation Licensing Examination
1993 Massachusetts License Registration
Academic Appointments:
1993-2005 Instructor in Pediatrics, Harvard Medical School, Boston, MA
2006- Assistant Professor in Pediatrics, Harvard Medical School, Boston, MA (expected)
Hospital Appointments:
1993-1994 Assistant in Pediatrics, Massachusetts General Hospital, Boston, MA
1994- Assistant Pediatrician, Massachusetts General Hospital, Boston, MA
2002- Consulting Staff in Pediatrics, Spaulding Rehabilitation Hospital, Boston, MA
2003- Consulting Staff in Pediatrics, Newton-Wellesley Hospital, Newton, MA
Awards and Honors:
1990-1992 Fogarty International Foundation Fellowship Award
1991 Lauri Strauss Leukemia Foundation Award
1994-1995 Charles Hood Foundation Award
1994-1995 American Cancer Society IRG
1995-1997 Clinical Investigator Award, National Cancer Institute
1997-2002 Howard Temin Award, National Cancer Institute
Professional Societies:
1988-1995 Member, German Society of Pediatric Oncology and Hematology
1995-2000 Member, Pediatric Oncology Group, US
2000- Member, Children’s Oncology Group, US
2005- Member, The Genetics Society of America
RESEARCH AND TEACHING CONTRIBUTIONS
A. Major Research Interests:
Epithelial morphogenesis, organogenesis and growth regulation in C. elegans
Development of cloning and gene knockout strategies in C. elegans
Cytoskeletal oncogenes and tumor suppressor genes
B. Narrative Report of Research
I am interested in the regulatory role of cytoskeletal genes at the juncture of cell shape formation and proliferation during development. The deregulation of this process may constitute a crucial step in tumorigenesis. In order to examine this process during the development of a living organism and to take advantage of its genetic versatility, I have moved from the study of vertebrate oncogenes/tumor suppressor genes to their invertebrate orthologs, and have focused in recent years on the nematode Caenorhabditis elegans.
My laboratory is part of the Research Program of the MassGeneral Hospital for Children’s Hematology-Oncology Department and is affiliated with the Gastroenterology Department. The laboratory is currently characterizing several FERM (protein 4.1-ezrin-radixin-moesin)–domain containing cytoskeletal genes in C. elegans, some of them are oncogene, others are tumor suppressor gene homologs. We have recently shown that one of these, the membrane-cytoskeleton linker erm-1, shapes the luminal surfaces of different tubular organs, such as the intestine, during development. We are currently conducting a genome-wide RNA interference screen on tubulogenesis in C. elegans, to identify novel genes with a role in epithelial morphogenesis and growth regulation. The emphasis of this screen is on intestinal morphogenesis, and this screen is also expected to identify the major genes regulating the development of the intestine.
The need to target mutations into specific C. elegans orthologs continues to drive my interest in the development of reverse genetic techniques. We have recently reported a novel knockout technique using gene conversion that allows engineered mutations to be targeted into the C. elegans genome. The absence of targeted gene alteration approaches such as homologous recombination in C. elegans has previously been a limitation in fully utilizing C. elegans as a genetic model system. This technique, if modified, should also be applicable in vertebrate systems.
My clinical research interests were originally directed towards the supportive care of children treated with chemotherapy, and to the treatment of pediatric bone tumors, particularly Ewing’s sarcoma. I was the research assistant of the German Society of Pediatric Oncology Ewing’s Sarcoma trial (H Juergens). Subsequently, I briefly served as the research assistant of the German Society of Pediatric Oncology Wilms Tumor Trial (W Ludwig). With a growing interest in the investigation of the underlying causes of malignancies, I then focused on studies on growth regulation and apoptosis in tumor cell lines, pre-B-cell lymphoblasts, and hematopoeisis (KM Debatin, P Krammer). At this time, I was also a member of the clinical Pediatric Hematology/Immunology Laboratory of the University of Heidelberg. I then broadened my research into molecular genetics with the investigation of vertebrate growth regulating genes at the National Cancer Institute, Bethesda (TA Waldmann, IR Kirsch).
C. Research Funding Information:
1984-1985 German Ministry for Research and Technology Research Fellowship PI: H Jürgens
The Cooperative Ewing’s Sarcoma Study of the German Society of Pediatric Oncology
1985-1987 German Society of Pediatric Oncology Research Fellowship
PI: R Ludwig
The Multicenter Wilms Tumor Study of the German Society of Pediatric Oncology
1988-1989 Heidelberg University Children’s Hospital Research Fellowship
Lab Heads: KM Debatin and P Krammer
Apoptosis mediated by Apo-1 in normal hematopoiesis and in leukemias
1990-1992 Fogarty International Foundation Research Fellowship
Lab Heads: TA Waldmann and I Kirsch
The helix-loop-helix transcription factors SCL and NSCL in hematopoiesis and in the development of the nervous system
1990-1991 Lauri Strauss Leukemia Foundation Research Grant
Lab Heads:TA Waldmann and I Kirsch
The role of the stem cell leukemia gene SCL in heamtopoiesis
1994-1995 Charles Hood Foundation
PI: V Göbel
Neurofibromatosis 2 tumor suppressor gene homologs in C.elegans.
1994-1995 American Cancer Society IRG (729-7019-5)
PI: V Göbel
Neurofibromatosis 2 tumor suppressor gene homologs in C.elegans.
1995-1997 NIH (K08 CA68475)
PI: V Göbel
NF2 tumor suppressor gene homologs in C. elegans.
This grant was awarded for two years only, and the application for a subsequent K01 was encouraged.
1997-2002 NIH (K01 CA74243)
PI: V Göbel
Tumor suppressor gene homologs in C. elegans.
D. Current Research Activities (Bench Research):
2003-2005 NIH (R03 HD44589)
PI: V Göbel
Organ lumen morphogenesis in C. elegans.
E. Report of Teaching:
1. Medical School Courses
1980-1981 Hormones and Immunology, Freie Universität Berlin, Department of Biochemistry
2. Graduate Medical Courses
1984-1985 General Pediatrics, Universität Düsseldorf, Department of Pediatrics
1985-1990 General Pediatrics and Pediatric Oncology, Universität Heidelberg, Department of Pediatrics
3. Advisory and Supervisory Responsibilities
1993- Pediatric Hematology-Oncology, Attending Physician MassGeneral Hospital for Children
1994- Molecular Biology/Genetics, PI MassGeneral Hospital for Children
F. Report of Clinical Activities:
1993- Attending physician in the Pediatric Hematology-Oncology Department at the MassGeneral Hospital for Children.
BIBLIOGRAPHY
Original reports:
1. Jürgens H, Göbel V, Michaelis J, Ramach W, Ritter J, Sauer R, Treuner J, Voûte PA, Winkler K, Göbel U. The Cooperative Ewing’s sarcoma Study CESS 81 of the German Pediatric Oncology Society. Klin Pädiatr 1985; 197: 225-232.
2. Jürgens H, Etspüler G, Göbel V, Göbel U, Graf N, Harms D, Ritter J, Salzer-Kuntschik M, Spaar HJ. Protochemotherapy in Ewing’s sarcoma: results of the German Society of Pediatric Oncology CESS 81 trial. Colloque Inserm 1986; 137: 539-597.
3. Göbel V, Jürgens H, Thomas L, Schwamborn D, Rosin H, Göbel U. Microbial spectrum of blood and body cultures in febrile episodes of children under chemotherapy for treatment of malignant diseases. Pediatr Hematol Oncol 1987; 4: 7-13.
4. Göbel V, Jürgens H, Etspüler G, Kemperdick H, Jungblut RM, Stienen U, Göbel U. Prognostic significance of tumor volume in localized Ewing’s sarcoma of bone in children and adolescents. J Cancer Res Clin Oncol 1987; 113: 187-191.
5. Beck JD, Bier V, Jürgens H, Brandeis W, Etspüler G, Gadner H, Göbel U, Schmidt H, Harms D. Malignant peripheral neuroepithelial tumors in childhood. Monatsschr Kinderheilkd 1987; 135: 214-217.
6. Bier V, Jürgens H, Etspüer G, Exner U, Kühl J, Ritter J, Winkler K, Göbel U. 120 hour continuous infusion of ifosfamide alone and in combination with cisplatinum in children and adolescents. In: Brade W, Nage GA, Seeber S. Ifosfamide in tumor therapy. Basel 1987: 131-138.
7. Jürgens H, Bier V, Harms D, Beck J, Brandeis W, Etspüler G, Gadner HY, Schmidt D, Treuner J, Winkler K, Göbel U. Malignant peripheral neuroectodermal tumors. A retrospective analysis of 42 patients. Cancer 1988; 61: 349-357.
8. Jürgens H, Bier V, Dunst J, Harms D, Jobke A, Kotz R, Kühl J, Müller-Weihrich S, Ritter J, Salzer-Kuntschik M, Sauer R, Sternschulte W, Treuner J, Voûte PA, Weinel P, Winkelmann W, Winkler K, Göbel U. The German Society of Pediatric Oncology Cooperative Ewing’s Sarcoma Studies CESS 81 and 86: report after 61/2 years. Klin Pädiatr 1988; 200: 243-252.
9. Bier V, Brandeis WE. Resection of a primary unresectable pelvic Ewing’s sarcoma after local hyperthermia in combination with systemic chemotherapy. Der Chirurg 1988; 59: 739.
10. Semmler W, Gademann G, Bachert-Baumann P, Bier V, Zabel HJ, Lorenz WJ, von Kaick G. In vivo 31phosphorus-spectroscopy of tumors: pre- intra- and post-therapy. RoFo 1988; 149: 369-377.
11. Begley CG, Lipkowitz S, Göbel V, Mahon KA, Bertness V, Green AR, Gough NM, Kirsch IR. Molecular characterization of NSCL, a gene encoding a helix-loop-helix protein expressed in the developing nervous system. Proc Natl Acad Sci USA 1992; 89: 38-42.
12. Göbel V, Lipkowitz S, Kozak CA, Kirsch IR. NSCL-2: a basic domain helix-loop-gene expressed in early neurogenesis. Cell Growth and Differ 1992; 3: 143-148.
13. Lipkowitz S, Göbel V, Varterasian ML, Nakahara K, Tchorz K, Kirsch IR. A comparative structural characterization of the human NSCL-1 and NSCL-2 genes. Two basic helix-loop-helix genes expressed in the developing nervous system. J Biol Chem 1992; 267: 21065-21071.
14. Göbel V, Hoffmann HG, Müller-Wiefel DE, Braun A, Ludwig R, Schärer K, Debatin KM. Circulating haematopoietic progenitors during treatment of renal anemia with recombinant human erythropoietin. Eur J Pediatr 1994; 153: 43-48.
15. Rämet M, Pearson A, Manfruelli P, Li X, Koziel H, Göbel V, Chung E, Krieger M, Ezekowitz RA. Drosophila scavenger receptor CI is a pattern recognition receptor for bacteria. Immunity 2001; 15: 1027-1038.
16. Göbel V, Barrett PL, Hall DH, Fleming JT. Lumen morphogenesis in C. elegans requires the membrane-cytoskeleton linker erm-1. Dev Cell 2004; 6: 865-873.
17. Barrett PL, Fleming JT, Göbel V. Targeted gene alteration in Caenorhabditis elegans by gene conversion. Nat Genetics 2004; 36: 1231-1237.
Proceedings of Meetings:
1. Jürgens H, Göbel V, Etspüler G, Kemperdick H, Michaelis J, Stienen U, Göbel U. Factors influencing the prognosis of children and adolescents with primary Ewing’s sarcoma of bone. Proc Am Soc Clin Oncol 1985; 4: 239.
2. Sauer R, Jürgens H, Göbel V, Michaelis J, Ramach W. The Ewing’s Sarcoma Study CESS 81 of the German Society of Pediatric Oncology: an analysis after 4 years. Int J Radiat Oncol Biol Phys 1985; 11 (Suppl 1): 88.
3. Göbel V, Etspüler G, Jürgens H, Sekera J, Schröder M, Winkler K, Göbel U. Ifosfamide alone and in combination with Cisplatinum in patients with recurrent Ewing’s sarcoma. First International Congress on Neoadjuvant Chemotherapy Proc 1985: 33.
4. Jürgens H, Etspüler G, Göbel V, Graf N, Spaar HJ, Ritter J, Göbel U. Protochemotherapy in Ewings’s sarcoma: results of the GPO-CESS 81 trial. First International Congress on Neoadjuvant Chemotherapy Proc 1985: 34.
5. Jürgens H, Geske C, Göbel V, Etspüler G, Göbel U. First site of recurrence in patients with Ewings’s sarcoma treated with protochemotherapy. International Society of Pediatric Oncology – SIOP XVII Proc 1985: 269 – 271.
6. Göbel V, Jürgens H, Etspüler G, Exner U, Kühl J, Ritter J, Winkler K, Göbel U. Effectiveness of Ifosfamide alone and in combination with Cisplatinum in patientswith recurrent Ewing’s sarcoma. J Cancer Res Clin Oncol Proc 1986; Suppl. 111: 30.
7. Göbel V, Jürgens H, Beck J, Brandeis W, Etspüler G, Gadner H, Harms D, Schmidt D, Sternschulte W, Treuner J, Göbel U. Malignant peripheral neuroectodermal tumors of childhood and adolescence. A retropsective analysis of treatment results in 30 patients. Proc Am Soc Clin Oncol 1986; 5: 206.
8. Jürgens H, Bier V, Bender-Götze CH, Burdach ST, Körbling M, Schaefer W, Urban CH, Göbel U. Bone marrow transplantation in multifocal Ewing’s Sarcoma. International Society of Pediatric Oncology - SIOP XIX Proc 1987: 82.
9. Jürgens H, Bier V, Müller-Weihrich ST, Ritter J, Sauer R, Treuner J, Voûte PA, Winkler K, Göbel U. Risk stratified chemotherapy in patients with primary Ewing’s sarcoma of bone: preliminary results of a cooperative study. Proc Am Soc Clin Oncol 1987: 7.
10. Debatin KM, Bier V, Mandl C, Trauth BC, Krammer PH. Expression of the Apo-1 antigen on acute lymphoblastic leukemia cells. 7th International Congress of Immunology Proc 1989: 45.
11. Bier V, Ludwig R. Comparative analysis of Wilms Tumor protocols: The National Wilms Tumor Study Group, The Societe Internationale Oncologie Pediatric and the German Society of Pediatric Oncology. Klin Padiatr 1988; Suppl German Society of Pediatric Oncology Meeting.
12. Bier V. Stem cell proliferation by Erythropoietin (invited presentation). European Society of Pediatric Research Proc 1990.
13. Hoffmann HG, Bier V, Debatin KM, Linderkamp O. Circulating haematopoietic progenitor cells in premature infants: their in-vitro response to erythropoietin and interleukin 3. European Society of Pediatric Research Proc 1990: 38.
14. Bier V, Debatin KM, Bosch A, Hoffmann HG, Müller-Wiefel DE, Ludwig R, Schärer K. Is interleukin 3 a critical hematopoietic growth factor in uremia? XXVIIth Congress of the European Dialysis and Transplant Association/European Renal Association Proc 1990.
15. Göbel V, Lipkowitz S, Varterasian M, Mahon KA, Gallo V, Kirsch IR. NSCL-1 and NSCL-2, two new basic helix-loop genes expressed during early neurologic development. Third Meeting on The Molecular Basis of Human Cancer Proc 1992: 3.
16. Lipkowitz S, Göbel V, Varterasian M, Kirsch IR. Characterization of NSCL-1 and NSCL-2: two basic domain helix-loop-genes expressed in the developing nervous system. Gordon Research Conference on Cancer Proc 1992.
17. Göbel V, Winge P, FitzGerald M, Moshiach S, Friend S, Fleming JT. Neurofibromatosis 2 Tumor Suppressor Gene Homologs in C. elegans. WBG 1994; 13(4): 61.
18. Winge P, Göbel V, Friend S, Fleming JT. R-ras-1 and R-ras-2 (TC21) Homologs in C. elegans. WBG 1994; 13(4): 67.
19. Olde B, McCombie R, Göbel V, Fleming JT. Cloning, Mammalian Expression and Knockout of a C. elegans Serotonin Receptor. WBG 1994; 13(4): 69
20. Göbel V, Fleming JT. The Neurofibromatosis 2 homolog (nf2) and its ezrin-radixin-moesin family member (erm) are essential genes in C. elegans. WBG 1998; 13(4): 47.
21. Göbel V, Barrett PL, Hall DH, Bossinger O, Fleming JT. The cytoskeletal linker ERM is required for the integrity of epithelial luminal surfaces of internal organs in C. elegans. International C. elegans Meetging Proc 2001: 444.
22. Barrett PL, Fleming JT, Bossinger O, Göbel V. Characterization of FERM-domain protein homologs in C. elegans. International C. elegans Meeting Proc 2001: 441.
23. van Fürden D, Theres C, Göbel V, Bossinger O. The role of erm-1 during zonlua adherens formation in the gut epithelium of C. elegans. International C. elegans Meeting Proc 2001: 512.
24. Göbel V, Barrett PL, Hall DH, Fleming JT. erm-1 models tubular epithelia in a junction-independent fashion and inhibits programmed cell death. International C. elegans Meeting Proc 2003: 763.
25. Göbel V, Barrett PL, Hall DH, Fleming JT. A cytoskeletal luminal matrix is essential for apical membrane morphogenesis of tubular epithelia. International C. elegans Meeting Proc 2005: 225.
26. Barrett PL, Fleming JT, Bossinger O, Göbel V. Targeted gene alteration in C. elegans via gene conversion. International C. elegans Meeting Proc 2005: 513.
27. Göbel V, Kim A, Barrett PL, Hall DH, Fleming JT. nfm-1, the C. elegans Neurofibromatosis 2 ortholog, is a basolateral protein required for morphogenesis of polarized epithelia. International C. elegans Meeting Proc 2005: 389.
Reviews, Chapters, & Editorials:
1. Krammer PH, Behrmann I, Bier V, Daniel P, Dhein J, Falk MH, Garcin G, Klas C, Knipping E, Lucking-Famira KM, Matzku S, Oehm A, Richards S, Trauth BC, Bornkamm GW, Falk W, Möller P, Debatin KM. Apoptosis in the Apo-1 system. Curr Commun Cell Mol Biol 1991; 3: 87-99.
2. Barrett PL, Fleming JT, Göbel V. Targeting and altering genes by geneconversion. A practical guide. (in press) Wormbook, ed. The C. elegans Research Community, WormBook, doi/10.1895/wormbook.1.7.1, http://www.wormbook.org
Dissertation:
Göbel V. Septicemia in immunocompromized children with malignancies. 1986, Heinrich-Heine University of Düsseldorf, Germany.
|
|
